Prevention of Ulcerative Colitis in Mice by Sweet Tea (Lithocarpus litseifolius) via the Regulation of Gut Microbiota and Butyric-Acid-Mediated Anti-Inflammatory Signaling

He, Xiao-Qin; Liú, Dan; Liu, Hongyan; Wu, Ding‐Tao; Li, Hua Bin; Zhang, Xin-Shang; Gan, Ren‐You

doi:10.3390/nu14112208

Cited by 27 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Supplementation of myricetin could effectively reverse gut dysbiosis that occurred in the HFD þ DSS group. Studies revealed that bacteria, such as Muribaculaceae (Mo et al, 2022), Lactobacillus (Rangan et al, 2019), Lachnospir-aceae_NK4A136_group (He et al, 2022), Blautia (Liu et al, 2021), Alistipes (Guo et al, 2021) were considered as beneficial bacteria in IBD.…”

Section: Discussionmentioning

confidence: 99%

Myricetin attenuates the inflammatory bowel disease in prediabetic mice via inflammation inhibition and gut microbiota modulation

Yang,

Gao,

Wang

et al. 2024

Food Safety and Health

View full text Add to dashboard Cite

Myricetin shows great anti‐inflammatory effect on colitis and supplementation with myricetin could improve gut microbiota dysbiosis. It is reported that the abnormal blood glucose condition of prediabetes could aggravate the progression of inflammation. However, there is no report on whether myricetin has the protective effect on inflammation comorbid prediabetes. This study aimed to explore the effect and potential mechanism of myricetin on dextran sulfate sodium (DSS)‐induced colitis in prediabetic mice. Several indexes related to colitis were evaluated on DSS‐induced prediabetic mice. Myricetin intervention improved body weight loss, disease activity index score in DSS‐induced colitis in prediabetic mice. Myricetin alleviated inflammation by inhibiting proinflammatory cytokines and myeloperoxidase production in DSS‐induced colitis in prediabetic mice. Furthermore, myricetin showed recovery of intestinal barrier integrity by increasing the expression of tight junction proteins (ZO‐1, Occludin and Claudin‐1). At the gut microbiota level, myricetin showed protective effects via modulating gut dysbiosis associated with DSS‐induced colitis in prediabetic mice. In addition, myricetin could significantly increase the short chain fatty acids produced by gut microbiota. Myricetin may be serving as a novel therapeutic agent which could be used in the treatment of DSS‐induced colitis in prediabetic patients in the future with its added value as well reported antidiabetic agent.

show abstract

Section: Discussionmentioning

confidence: 99%

Myricetin attenuates the inflammatory bowel disease in prediabetic mice via inflammation inhibition and gut microbiota modulation

Yang,

Gao,

Wang

et al. 2024

Food Safety and Health

View full text Add to dashboard Cite

show abstract

“…Lachnospiraceae_NK4A136 group belongs to the family Lachnospiraceae and is a potentially beneficial bacterium associated with obesity. It is also related to the production of butyric acid ( 45 , 46 ). Ruminococcus play a crucial role in metabolism.…”

Section: Discussionmentioning

confidence: 99%

The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial

et al. 2023

View full text Add to dashboard Cite

ObjectiveAs a metabolic disease, one important feature of non-alcoholic fatty liver disease (NAFLD) is the disturbance of the intestinal flora. Spleen-strengthening and liver-draining formula (SLF) is a formula formed according to the theory of “One Qi Circulation” (Qing Dynasty, 1749) of Traditional Chinese Medicine (TCM), which has shown significant therapeutic effect in patients with NAFLD in a preliminary clinical observation. In this study, we aim to explore the mechanism of SLF against NAFLD, especially its effect on glucolipid metabolism, from the perspective of intestinal flora.MethodsA prospective, randomized, controlled clinical study was designed to observe the efficacy and safety of SLF in the treatment of NAFLD. The study participants were randomly and evenly divided into control group and treatment group (SLF group). The control group made lifestyle adjustments, while the SLF group was treated with SLF on top of the control group. Both groups were participated in the study for 12 consecutive weeks. Furthermore, the feces of the two groups were collected before and after treatment. The intestinal flora of each group and healthy control (HC) were detected utilizing 16S rRNA gene sequencing.ResultsCompared with the control group, the SLF group showed significant improvements in liver function, controlled attenuation parameter (CAP), and liver stiffness measurement (LSM), meanwhile, patients had significantly lower lipid and homeostasis model assessment of insulin resistance (HOMA-IR) with better security. Intestinal flora 16S rRNA gene sequencing results indicated reduced flora diversity and altered species abundance in patients with NAFLD. At the phylum level, Desulfobacterota levels were reduced. Although Firmicutes and Bacteroidetes did not differ significantly between HC and NAFLD, when grouped by alanine transaminase (ALT) and aspartate transaminase (AST) levels in NAFLD, Firmicutes levels were significantly higher in patients with ALT or AST abnormalities, while Bacteroidetes was significantly lower. Clinical correlation analysis showed that Firmicutes positively correlated with gender, age, ALT, AST, LSM, and Fibroscan-AST (FAST) score, while the opposite was true for Bacteroidetes. At the genus level, the levels of Alistipes, Bilophila, Butyricimonas, Coprococcus, Lachnospiraceae_NK4A136 group Phascolarctobacterium, Ruminococcus, UCG-002, and UCG-003 were reduced, whereas abundance of Tyzzerella increased. There was no statistically significant difference in Firmicutes and Bacteroidota levels in the SLF group before and after treatment, but both bacteria tended to retrace. At the genus level, Coprococcus (Lachnospiraceae family), Lachnospiraceae_NK4A136 group (Lachnospiraceae family), and Ruminococcus (Ruminococcaceae family) were significantly higher in the SLF group after treatment, and there was also a tendency for Bilophila (Desulfovibrionaceae family) to be back-regulated toward HC.ConclusionsSLF can improve liver function and glucolipid metabolism in patients with NAFLD and lower down liver fat content to some extent. SLF could be carried out by regulating the disturbance of intestinal flora, especially Coprococcus, Lachnospiraceae_NK4A136 group, and Ruminococcus genus.

show abstract

“…The results showed that the abundance of Lactobacillus had a highly positive correlation with the SCFAs profiles while it had negative correlations with inflammatory factors, which were conducive to the suppression of intestinal inflammation. Lachnospiraceae_NK4A136_group is a kind of SCFAs−producing bacteria that promotes the biosynthesis of butyric acid [ 47 , 48 ]. We found that the abundance of the Lachnospiraceae_NK4A136_group was significantly increased in the DSS group, whereas its increase was also observed in the BUR groups.…”

Section: Discussionmentioning

confidence: 99%

Bisdemethoxycurcumin Alleviates Dextran Sodium Sulfate-Induced Colitis via Inhibiting NLRP3 Inflammasome Activation and Modulating the Gut Microbiota in Mice

Zhang

Chen

et al. 2022

Antioxidants

View full text Add to dashboard Cite

Our previous study showed that bisdemethoxycurcumin (BUR) exerts anti-inflammatory properties in lipopolysaccharide-induced intestinal injury, and studies have revealed that NOD-like receptor superfamily, pyrin domain containing 3 (NLRP3) inflammasome activation plays a vital role in the pathogenesis of colitis. However, it is not clear whether BUR could attenuate colitis-mediated intestinal inflammation via NLRP3 inflammasome inactivation and modulate the gut microbiota dysbiosis. The results demonstrated that BUR attenuated DSS-induced body weight decrease, histopathological changes, and epithelial apoptosis. BUR significantly improved the intestinal barrier defects and abrogated DSS-induced inflammatory response. Consistently, BUR reduced the expression of NLRP3 family members, confirming its inhibitory effects on NLRP3 inflammasome activation and pyroptosis. BUR regulated microbiota dysbiosis and altered the gut microbial community. BUR supplementation enriched the relative abundance of beneficial bacteria (such as Lactobacillus and Bifidobacterium), which showed significant negative correlations with the pro-inflammatory biomarkers. Collectively, these findings illustrated that BUR could ameliorate DSS-induced colitis by improving intestinal barrier function, reducing apoptosis, inhibiting NLRP3 inflammasome activation, and regulating the gut microbiota.

show abstract

Prevention of Ulcerative Colitis in Mice by Sweet Tea (Lithocarpus litseifolius) via the Regulation of Gut Microbiota and Butyric-Acid-Mediated Anti-Inflammatory Signaling

Cited by 27 publications

References 41 publications

Myricetin attenuates the inflammatory bowel disease in prediabetic mice via inflammation inhibition and gut microbiota modulation

Myricetin attenuates the inflammatory bowel disease in prediabetic mice via inflammation inhibition and gut microbiota modulation

The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial

Bisdemethoxycurcumin Alleviates Dextran Sodium Sulfate-Induced Colitis via Inhibiting NLRP3 Inflammasome Activation and Modulating the Gut Microbiota in Mice

Contact Info

Product

Resources

About